Bausch Health Companies Inc (NYSE:BHC) – Analysts at Jefferies Financial Group lowered their Q2 2019 EPS estimates for shares of Bausch Health Companies in a report released on Thursday, August 1st. Jefferies Financial Group analyst D. Steinberg now expects that the company will earn $1.00 per share for the quarter, down from their previous estimate of $1.08. Jefferies Financial Group also issued estimates for Bausch Health Companies’ Q3 2019 earnings at $0.99 EPS, FY2020 earnings at $4.49 EPS, FY2021 earnings at $4.88 EPS, FY2022 earnings at $5.18 EPS and FY2023 earnings at $5.59 EPS.
A number of other research firms have also recently issued reports on BHC. ValuEngine raised Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research report on Monday, July 29th. Piper Jaffray Companies set a $29.00 price objective on Bausch Health Companies and gave the company a “buy” rating in a research report on Tuesday, June 11th. JPMorgan Chase & Co. raised Bausch Health Companies from an “underweight” rating to a “neutral” rating and set a $24.80 price objective for the company in a research report on Monday, May 13th. Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a research report on Monday, July 15th. Finally, Mizuho set a $45.00 price objective on Bausch Health Companies and gave the company a “buy” rating in a research report on Thursday, June 20th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company’s stock. Bausch Health Companies presently has a consensus rating of “Hold” and a consensus target price of $29.43.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Monday, May 6th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.14. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The company had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period last year, the firm posted $0.89 earnings per share. The business’s revenue was up 1.1% on a year-over-year basis.
In related news, EVP Christina Ackermann sold 3,968 shares of Bausch Health Companies stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $24.81, for a total transaction of $98,446.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.87% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in BHC. Geode Capital Management LLC raised its stake in shares of Bausch Health Companies by 8.9% during the fourth quarter. Geode Capital Management LLC now owns 258,186 shares of the company’s stock valued at $4,740,000 after purchasing an additional 21,074 shares during the period. Macquarie Group Ltd. purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $418,000. APG Asset Management N.V. raised its stake in shares of Bausch Health Companies by 59.3% during the fourth quarter. APG Asset Management N.V. now owns 139,354 shares of the company’s stock valued at $2,253,000 after purchasing an additional 51,900 shares during the period. Norges Bank purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $59,054,000. Finally, Hayden Royal LLC raised its stake in shares of Bausch Health Companies by 36.5% during the first quarter. Hayden Royal LLC now owns 52,674 shares of the company’s stock valued at $1,301,000 after purchasing an additional 14,072 shares during the period. 53.72% of the stock is owned by institutional investors and hedge funds.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Further Reading: Range Trading
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.